rHSC-DIPGVax + Checkpoint Inhibitors for Brain Tumor

Recruiting at 2 trial locations

Overseen By Monica Newmark, BS, RN

Age: < 65

Sex: Any

Trial Phase: Phase 1

Sponsor: Ann & Robert H Lurie Children's Hospital of Chicago

Must not be taking: Temozolomide

Disqualifiers: Disseminated disease, Autoimmune, Respiratory, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

36 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests a new treatment combination for brain tumors known as DIPG and DMG. The researchers aim to determine if the vaccine rHSC-DIPGVax, combined with two other drugs, Balstilimab and Zalifrelimab (both checkpoint inhibitors), is safe and tolerable. The treatment targets specific markers found in most of these brain tumors. Suitable candidates for this trial are those newly diagnosed with DIPG or DMG who completed radiation therapy 6-10 weeks ago. As a Phase 1 trial, this research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this new therapy.

Will I have to stop taking my current medications?

The trial protocol does not specify if you need to stop taking your current medications, but you cannot receive temozolomide during radiation. Corticosteroids should be reduced to 0.5mg/kg/day or less for at least 7 days before joining the trial.

Is there any evidence suggesting that this trial's treatments are likely to be safe?

Research shows that rHSC-DIPGVax helps the immune system fight tumors by using a mix of proteins to target common tumor features. Studies have shown this method boosts the immune system without major safety concerns.

For Balstilimab, research indicates it is safe when combined with other tumor treatments. No serious side effects were reported, suggesting patients generally tolerated it well.

Zalifrelimab has been studied for brain tumors, and large trials did not find additional harm to the nervous system. This suggests it is relatively safe, though careful monitoring remains important.

This trial is in its early phase, focusing on confirming safety and how well participants tolerate the treatments. While earlier studies are promising, the primary aim is to ensure these treatments are safe for participants. ^{1 2 3 4 5}

Why are researchers excited about this trial's treatments?

Unlike the standard care for brain tumors, which often revolves around radiation and chemotherapy, the investigational treatments—rHSC-DIPGVax in combination with Balstilimab and Zalifrelimab—take a novel approach by leveraging the body's immune system. rHSC-DIPGVax is a vaccine designed to stimulate an immune response specifically against brain tumor cells. Balstilimab and Zalifrelimab are checkpoint inhibitors that help the immune system recognize and attack cancer cells more effectively. Researchers are excited because this combination could offer a more targeted and potentially more effective treatment, with the hope of improving outcomes for patients where traditional therapies fall short.

What evidence suggests that this trial's treatments could be effective for brain tumors?

Research has shown that rHSC-DIPGVax, one of the treatments in this trial, is a promising cancer vaccine designed to help the immune system target brain tumors like DIPG and DMG. It uses special proteins to teach the body to recognize and attack tumor cells. Early results suggest this method can enhance the immune system's ability to fight these aggressive tumors.

In this trial, some participants will receive Balstilimab, a type of medicine called a checkpoint inhibitor. Studies have found that it helps patients with various cancers live longer by keeping the immune system active against cancer cells for an extended period. Others will receive Zalifrelimab, another immune-boosting treatment, which has shown positive results in animal studies, especially when combined with other treatments. This suggests it might aid in treating stubborn brain tumors. Together, these treatments aim to strengthen the immune response against brain tumors. ^{2 3 6 7 8}

Who Is on the Research Team?

Ashley Plant-Fox, MD

Principal Investigator

Ann and Robert H. Lurie Children's Hospital

Are You a Good Fit for This Trial?

This trial is for children and teens (12 months to 18 years old) with newly diagnosed brain tumors called DIPG or DMG, who've finished radiation therapy recently. They need a confirmed histone mutation and measurable disease. Kids should be able to perform daily activities at least halfway normally, even if in a wheelchair, and not have received any cancer treatment other than radiation.

Inclusion Criteria

Biopsy is not required for subjects with radiographically typical DIPG meeting imaging criteria

I am between 1 and 18 years old.

I have reduced my steroid use to less than or equal to 0.5mg/kg/day for at least 7 days.

Exclusion Criteria

I currently have a lung infection or breathing problem.

Autoimmune or immune disorders

I am not taking temozolomide with my radiation therapy.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Lead In

Initial study to assess the tolerability of rHSC-DIPGVax monotherapy in older children

8 doses

Part A

Evaluation of rHSC-DIPGVax in combination with BALSTILIMAB for safety and tolerability

1 year or 27 cycles, whichever comes first

Part B

Dose escalation of ZALIFRELIMAB in combination with rHSC-DIPGVax and BALSTILIMAB

1 year or 9 cycles, whichever comes first

Part C

Expansion arm to assess futility versus efficacy at RP2D of ZALIFRELIMAB

1 year or 9 cycles, whichever comes first

Follow-up

Participants are monitored for safety and effectiveness after treatment

3 months

What Are the Treatments Tested in This Trial?

Interventions

• Balstilimab
• rHSC-DIPGVax
• Zalifrelimab

Trial Overview

The trial tests rHSC-DIPGVax combined with two immune checkpoint inhibitors, Balstilimab and Zalifrelimab. It's an early-phase study focusing on safety and how well patients tolerate the treatment. The vaccine targets specific tumor markers while the drugs aim to boost the immune system against the tumor.

How Is the Trial Designed?

Group I: Part C: Dose Expansion Experimental Treatment 3 Interventions

rHSC-DIPGVax (8 total doses) + BALSTILIMAB + ZALIFRELIMAB (at RP2D from Part B) (1 year of therapy or 9 cycles, whichever comes first) Patients will enroll 6-10 weeks post standard of care (SOC) radiation therapy. Steroid dose must be at or below 0.5mg/kg/day for a minimum of 7 days. Up to 12 patients will be enrolled on Part C. All subjects in Part C will be monitored for DLT's for the duration of their participation in the study to monitor for excess toxicity.

Group II: Part B: Dose Escalation of ZALIFRELIMAB (Anti-CTLA4) Experimental Treatment 3 Interventions

rHSC-DIPGVax (8 total doses) + BALSTILIMAB + ZALIFRELIMAB (1 year of therapy or 9 cycles, whichever comes first) Patients will enroll 6-10 weeks post standard of care (SOC) radiation therapy. Steroid dose must be at or below 0.5mg/kg/day for a minimum of 7 days. The first 3 patients must be 5 years or older to 18. Subsequently, subjects ages 12 months to 18 years can be enrolled. Up to 12 patients will be enrolled on Part B. Once safety is established for rHSC-DIPGVax plus anti-PD1 (BALSTILIMAB) plus anti-CTLA4 (ZALIFRELIMAB), the study will proceed to Part C.

Group III: Part A: rHSC-DIPGVax in Combination with BALSTILIMAB (Anti-PD1) Experimental Treatment 2 Interventions

rHSC-DIPGVax (8 total doses) + BALSTILIMAB (1 year of therapy or 27 cycles, whichever comes first) Patients will enroll 6-10 weeks post standard of care (SOC) radiation completion. Steroid dose must be at or below 0.5mg/kg/day for a minimum of 7 days. The first 3 patients must be 5 years or older to 18. Subsequently, subjects ages 12 months to 18 years can be enrolled. Up to six patients will be enrolled on Part A. Once safety is established for rHSC-DIPGVax plus anti-PD1 (BALSTILIMAB), the study will proceed to Part B.

Group IV: "Lead In": rHSC-DIPGVax Monotherapy Experimental Treatment 1 Intervention

rHSC-DIPGVax for 8 total doses

Who Is Running the Clinical Trial?

Ann & Robert H Lurie Children's Hospital of Chicago

Lead Sponsor

Trials

275

Recruited

5,182,000+

Dana-Farber Cancer Institute

Collaborator

Trials

1,128

Recruited

382,000+

Children's Hospital of Orange County

Collaborator

Trials

38

Recruited

5,700+

University of Calgary

Collaborator

Trials

827

Recruited

902,000+

Published Research Related to This Trial

Palbociclib, when combined with temsirolimus, effectively inhibits the growth of diffuse intrinsic pontine glioma (DIPG) cells in vitro by targeting CDK4/6 and mTOR signaling pathways, showing synergistic effects across three patient-derived cell lines.

Direct infusion of palbociclib into the brain did not cause neurotoxicity, suggesting a potentially safe method for delivering this treatment in combination with temsirolimus for DIPG, a type of pediatric brain tumor resistant to conventional therapies.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Combined use of CDK4/6 and mTOR inhibitors induce synergistic growth arrest of diffuse intrinsic pontine glioma cells via mutual downregulation of mTORC1 activity. Asby, DJ., Killick-Cole, CL., Boulter, LJ., et al.[2022]

In a study of 30 patients with advanced pancreatic ductal adenocarcinoma, combining ipilimumab (10 mg/kg) with the GVAX vaccine led to prolonged disease stabilization in 3 patients and a decline in CA19-9 levels, indicating a potential therapeutic benefit.

The combination treatment also showed a trend towards improved overall survival (5.7 months) compared to ipilimumab alone (3.6 months), suggesting that this approach may enhance the effectiveness of cancer immunotherapy, although further studies are needed.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. Le, DT., Lutz, E., Uram, JN., et al.[2022]

The oncolytic virus Delta-24-RGD has been shown to be safe and significantly increase survival in mouse models of pediatric high-grade glioma (pHGG) and diffuse intrinsic pontine gliomas (DIPGs), indicating its potential as a treatment option.

The therapeutic effect of Delta-24-RGD is attributed to both its ability to directly kill tumor cells and to stimulate an immune response against the tumors, leading to the initiation of a phase I/II clinical trial for newly diagnosed DIPG patients.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models. Martínez-Vélez, N., Garcia-Moure, M., Marigil, M., et al.[2021]

The first three patients with diffuse intrinsic pontine glioma (DIPG) treated with B7-H3-specific CAR T cells showed no dose-limiting toxicities after receiving 40 infusions, indicating the treatment's safety and tolerability.

One patient experienced sustained clinical and radiographic improvement for 12 months, suggesting potential efficacy, while the presence of CAR T cells in cerebrospinal fluid (CSF) and local immune activation were observed, supporting the treatment's mechanism of action.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Intraventricular B7-H3 CAR T Cells for Diffuse Intrinsic Pontine Glioma: Preliminary First-in-Human Bioactivity and Safety. Vitanza, NA., Wilson, AL., Huang, W., et al.[2023]

Recent studies suggest that targeting specific vulnerabilities in DIPG cells, such as using epigenetic modifying agents like histone deacetylase inhibitors and CDK7 inhibitors, may offer new therapeutic options.

Emerging immunotherapies and strategies to disrupt the tumor's supportive microenvironment are being explored, indicating that a combination of approaches will likely be necessary to effectively treat this aggressive childhood brain tumor.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Diffuse intrinsic pontine glioma: molecular landscape and emerging therapeutic targets. Aziz-Bose, R., Monje, M.[2020]

In a review of 18 studies involving 4,653 patients, anti-CTLA-4 inhibitors were associated with a significantly higher incidence of diarrhea (35.4%) and colitis (8.8%) compared to anti-PD-1 inhibitors, which had incidences of 13.7% and 1.6%, respectively.

The study found that patients receiving anti-PD-1 therapy had a lower relative risk of developing diarrhea (0.58) and colitis (0.16) compared to those on anti-CTLA-4 therapy, indicating that PD-1 inhibitors may be a safer option regarding these gastrointestinal toxicities.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

The Risk of Diarrhea and Colitis in Patients With Advanced Melanoma Undergoing Immune Checkpoint Inhibitor Therapy: A Systematic Review and Meta-Analysis. Tandon, P., Bourassa-Blanchette, S., Bishay, K., et al.[2019]

Diffuse intrinsic pontine glioma (DIPG) is a highly aggressive brainstem tumor in children with no effective treatments beyond radiation therapy, which only provides temporary relief.

Recent insights suggest that DIPG is biologically distinct from other high-grade gliomas, indicating that existing chemotherapy and targeted therapies should not be adapted for DIPG, and that new approaches, including better drug delivery methods and tumor models, are needed for effective treatment.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

DIPG in Children - What Can We Learn from the Past? Vanan, MI., Eisenstat, DD.[2022]

The H3.3K27M-targeted peptide vaccine was well tolerated in patients with diffuse midline gliomas, with no severe treatment-related adverse events reported, indicating a favorable safety profile.

Patients who developed H3.3K27M-reactive CD8+ T cell responses had a significantly longer overall survival (median OS of 16.1 months) compared to those who did not respond, highlighting the potential efficacy of the vaccine in improving outcomes for these patients.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Mass cytometry detects H3.3K27M-specific vaccine responses in diffuse midline glioma. Mueller, S., Taitt, JM., Villanueva-Meyer, JE., et al.[2022]

The study involved 9 children with newly diagnosed diffuse intrinsic pontine glioma (DIPG) and demonstrated that autologous dendritic cell vaccines (ADCV) can be safely prepared and administered after radiation therapy, with no adverse effects reported.

Immunological responses to the ADCV were observed in nearly all patients, indicating a specific immune response against DIPG, which suggests that this approach could be a promising foundation for future immunotherapy strategies.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Immune Response Generated With the Administration of Autologous Dendritic Cells Pulsed With an Allogenic Tumoral Cell-Lines Lysate in Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma. Benitez-Ribas, D., Cabezón, R., Flórez-Grau, G., et al.[2022]

Nivolumab, an immune checkpoint inhibitor, shows strong antitumor activity but is associated with immune-related adverse events that can affect patient safety and treatment continuation, necessitating careful monitoring.

Long-term safety data, including a 5-year follow-up, suggests that nivolumab can be safely administered to various challenging patient subgroups, but identifying biomarkers for severe toxicity could improve patient selection for this therapy.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

An update on the safety of nivolumab for the treatment of advanced melanoma. Czarnecka, AM., Rutkowski, P.[2021]

In a study of 104 advanced melanoma patients in Korea, ipilimumab demonstrated similar efficacy and safety profiles as seen in Western populations, with a median progression-free survival of 2.73 months.

The most common adverse event was skin rash, affecting 22.1% of patients, and factors like poor performance status and liver metastasis were identified as independent poor prognostic indicators.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Ipilimumab Real-World Efficacy and Safety in Korean Melanoma Patients from the Korean Named-Patient Program Cohort. Jung, M., Lee, J., Kim, TM., et al.[2022]

Ipilimumab is a monoclonal antibody that blocks CTLA-4, enhancing T-cell activation and leading to significant antitumor immune responses, which has been shown to improve survival in patients with advanced melanoma in two global phase 3 clinical studies involving over 13,000 patients.

Approved in over 40 countries, including the U.S. and EU, ipilimumab is the first treatment to demonstrate an overall survival benefit for advanced melanoma, with ongoing trials exploring its efficacy in other cancers like lung and gastric cancer.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

[Ipilimumab]. Tokudome, T.[2017]

Immunomodulatory agents targeting CTLA4 and PD1/PDL1 have shown significant effectiveness in treating both primary and metastatic brain tumors, suggesting a promising avenue for cancer therapy.

Combining anti-CTLA4 and anti-PD1 therapies enhances clinical benefits compared to using them individually, although this combination may lead to increased toxicity, highlighting the need to understand the brain tumor microenvironment for better treatment predictions.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Primary and metastatic brain cancer genomics and emerging biomarkers for immunomodulatory cancer treatment. Passiglia, F., Caglevic, C., Giovannetti, E., et al.[2018]

Diffuse midline gliomas (DMGs) are highly aggressive pediatric tumors with a median overall survival of less than 12 months, highlighting the urgent need for new treatment options.

Immunotherapy, particularly anti-GD2 CAR-T therapy, shows promise in treating DMGs, especially in diffuse intrinsic pontine glioma (DIPG) patients, although challenges remain in translating early successes into standardized treatments.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Immunotherapy approaches for the treatment of diffuse midline gliomas. Bernstock, JD., Hoffman, SE., Kappel, AD., et al.[2022]

Citations

1.

targetedonc.com

targetedonc.com/view/botensilimab-and-balstilimab-prove-notable-os-in-patients-with-advanced-solid-tumors

Botensilimab and Balstilimab Prove Notable OS in ...

Botensilimab and balstilimab showed promising survival outcomes in advanced solid tumors, with a median OS of 17.2 months and 39% 24-month ...

2.

pmc.ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov/articles/PMC12478451/

Cell therapies against brain tumors: Clinical development and ...

Clinical trials have continued to investigate the tolerability, efficacy, and long‐term outcomes of cell therapies for brain cancers. New advances in cell ...

3.

onclive.com

onclive.com/view/dr-schlechter-on-updated-data-for-botensilimab-plus-balstilimab-in-mss-mcrc

Dr Schlechter on Updated Data for Botensilimab Plus ...

Median progression-free survival (PFS) was 4.0 months (95% CI, 2.8-4.1), and the median overall survival (OS) reached 20.9 months (95% CI, 16.2- ...

4.

investor.agenusbio.com

investor.agenusbio.com/news/news-details/2024/Breakthrough-Data-on-BotensilimabBalstilimab-in-MSS-CRC-Presented-at-the-2024-ASCO-Annual-Meeting/default.aspx

Breakthrough Data on Botensilimab/Balstilimab in MSS ...

Across different NLM sites, overall response rates (ORR) ranged from 18-33% and disease control rates (DCR) ranged from 67-82%. Overall survival ...

5.

vbivaccines.com

vbivaccines.com/press-releases/agenus-collaboration/

VBI Vaccines and Agenus Announce Collaboration to ...

In the ongoing Phase 2a study, one recurrent GBM patient remains on protocol beyond two and a half years with a sustained 93% tumor reduction ...

6.

clinicaltrials.gov

clinicaltrials.gov/study/NCT02694822

AGEN1884, an Anti-CTLA-4 Human Monoclonal Antibody ...

This is an open-label, Phase 1/2, multicenter study to evaluate the safety, pharmacokinetics, and pharmacodynamics of an anti-cytotoxic T ...

7.

clinicaltrials.gov

clinicaltrials.gov/study/NCT06322108

Study Details | NCT06322108 | Assessment of the Safety ...

The goal of this study is to see if the combination of immunotherapy agents botensilimab and balstilimab is safe and effective in participants with metastatic ...

8.

onclive.com

onclive.com/view/neoadjuvant-botensilimab-plus-balstilimab-is-active-safe-regardless-of-mismatch-repair-status-in-solid-tumors

Neoadjuvant Botensilimab Plus Balstilimab Is Active, Safe ...

Botensilimab and balstilimab proved active and safe as neoadjuvant therapy in patients with mismatch repair–deficient and –proficient solid tumors.